Pliant Therapeutics (NASDAQ:PLRX - Free Report) had its target price trimmed by Royal Bank of Canada from $4.00 to $3.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a sector perform rating on the stock.
Several other research analysts have also commented on the company. Stifel Nicolaus lowered Pliant Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Oppenheimer reiterated a "market perform" rating on shares of Pliant Therapeutics in a report on Monday, February 10th. HC Wainwright cut Pliant Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, February 10th. JPMorgan Chase & Co. lowered shares of Pliant Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, February 10th. Finally, Leerink Partners cut shares of Pliant Therapeutics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $33.00 to $2.00 in a research report on Monday, March 3rd. Twelve research analysts have rated the stock with a hold rating, According to MarketBeat.com, Pliant Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $13.31.
View Our Latest Stock Report on PLRX
Pliant Therapeutics Trading Up 2.5 %
Shares of NASDAQ PLRX traded up $0.04 during trading on Tuesday, hitting $1.62. 1,636,036 shares of the company traded hands, compared to its average volume of 848,601. The firm has a market capitalization of $98.58 million, a P/E ratio of -0.49 and a beta of 1.18. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $8.11 and a 200-day moving average price of $11.50. Pliant Therapeutics has a 1 year low of $1.26 and a 1 year high of $16.52.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.17. On average, equities analysts predict that Pliant Therapeutics will post -3.64 EPS for the current year.
Insider Buying and Selling
In related news, insider Hans Hull sold 15,936 shares of the company's stock in a transaction on Friday, January 17th. The stock was sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the transaction, the insider now directly owns 211,558 shares in the company, valued at $2,369,449.60. This represents a 7.01 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Mike Ouimette sold 10,230 shares of the company's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total transaction of $112,427.70. Following the transaction, the general counsel now owns 70,544 shares of the company's stock, valued at $775,278.56. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,855 shares of company stock worth $1,026,628. Corporate insiders own 6.40% of the company's stock.
Institutional Investors Weigh In On Pliant Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of PLRX. Harbor Capital Advisors Inc. increased its stake in Pliant Therapeutics by 233.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 91,979 shares of the company's stock worth $1,031,000 after purchasing an additional 64,422 shares in the last quarter. Atria Investments Inc purchased a new position in shares of Pliant Therapeutics in the third quarter worth approximately $112,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Pliant Therapeutics during the third quarter valued at approximately $388,000. Intech Investment Management LLC purchased a new stake in shares of Pliant Therapeutics in the 3rd quarter valued at approximately $145,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Pliant Therapeutics by 4.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 456,663 shares of the company's stock worth $5,119,000 after purchasing an additional 19,281 shares during the period. 97.30% of the stock is currently owned by institutional investors.
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Featured Articles
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
